Literature DB >> 17395907

Erythropoiesis stimulating agents.

David P Steensma.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17395907      PMCID： PMC1839202          DOI： 10.1136/bmj.39163.536852.80

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

1.  Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity.

Authors:  W Mark Brown; Perry Maxwell; Alastair N J Graham; Anita Yakkundi; Elaine A Dunlop; Zhanzhong Shi; Patrick G Johnston; Terence R J Lappin
Journal:  Stem Cells       Date:  2006-11-16       Impact factor: 6.277

2.  Erythropoietin use in cancer patients: a matter of life and death?

Authors:  David P Steensma; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

3.  Erythropoietin: high profile, high scrutiny.

Authors:  Jeffrey Crawford
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

Review 4.  Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.

Authors:  Julia Bohlius; Simon Langensiepen; Guido Schwarzer; Jerome Seidenfeld; Margaret Piper; Charles Bennett; Andreas Engert
Journal:  J Natl Cancer Inst       Date:  2005-04-06       Impact factor: 13.506

5.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Authors:  Brian Leyland-Jones; Vladimir Semiglazov; Marek Pawlicki; Tadeusz Pienkowski; Sergei Tjulandin; George Manikhas; Antoly Makhson; Anton Roth; David Dodwell; Jose Baselga; Mikhail Biakhov; Konstantinas Valuckas; Edouard Voznyi; Xiangyang Liu; Els Vercammen
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

6.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

7.  Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

Authors:  James R Wright; Yee C Ung; Jim A Julian; Kathleen I Pritchard; Timothy J Whelan; Column Smith; Barbara Szechtman; Wilson Roa; Liam Mulroy; Leona Rudinskas; Bruno Gagnon; Gord S Okawara; Mark N Levine
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

8.  Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.

Authors:  Michael Henke; Roland Laszig; Christian Rübe; Ulrich Schäfer; Klaus-Dieter Haase; Burkhard Schilcher; Stephan Mose; Karl T Beer; Ulrich Burger; Chris Dougherty; Hermann Frommhold
Journal:  Lancet       Date:  2003-10-18       Impact factor: 79.321

9.  Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

Authors:  J Douglas Rizzo; Alan E Lichtin; Steven H Woolf; Jerome Seidenfeld; Charles L Bennett; David Cella; Benjamin Djulbegovic; Matthew J Goode; Ann A Jakubowski; Stephanie J Lee; Carole B Miller; Mark U Rarick; David H Regan; George P Browman; Michael S Gordon
Journal:  J Clin Oncol       Date:  2002-10-01       Impact factor: 44.544
  9 in total
  1 in total

Review 1.  Oxygen delivery enhancers: past, present, and future.

Authors:  P Borrione; A Mastrone; R A Salvo; A Spaccamiglio; L Grasso; A Angeli
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.